Cargando…
Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies
Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043635/ https://www.ncbi.nlm.nih.gov/pubmed/36999097 http://dx.doi.org/10.7759/cureus.35471 |
_version_ | 1784913194767089664 |
---|---|
author | Almaghrabi, Murouj Almatrafi, Shahad B Alzahrani, Asma Alharbi, Mohammed |
author_facet | Almaghrabi, Murouj Almatrafi, Shahad B Alzahrani, Asma Alharbi, Mohammed |
author_sort | Almaghrabi, Murouj |
collection | PubMed |
description | Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with proximal upper and lower limb weakness, dysphagia, dysarthria, and dyspnea with no previous medical or surgical history and was not on medication. Targeted myopathic antibody analysis revealed antibodies to signal recognition particles (SRP), and the serum creatinine kinase level reached 9308 U/L. A diagnosis of NAM was made, and the patient was started on the management plan. We discussed an interesting case progression and adverse effect challenges, as well as the management of these difficult-to-treat conditions. |
format | Online Article Text |
id | pubmed-10043635 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-100436352023-03-29 Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies Almaghrabi, Murouj Almatrafi, Shahad B Alzahrani, Asma Alharbi, Mohammed Cureus Internal Medicine Necrotizing autoimmune myopathy (NAM) is a rare muscular disorder characterized by severe proximal muscle weakness. Risk factors include statin use, malignancy, and connective tissue diseases. The current study presents the first case of NAM in Saudi Arabia in a 26-year-old female who presented with proximal upper and lower limb weakness, dysphagia, dysarthria, and dyspnea with no previous medical or surgical history and was not on medication. Targeted myopathic antibody analysis revealed antibodies to signal recognition particles (SRP), and the serum creatinine kinase level reached 9308 U/L. A diagnosis of NAM was made, and the patient was started on the management plan. We discussed an interesting case progression and adverse effect challenges, as well as the management of these difficult-to-treat conditions. Cureus 2023-02-25 /pmc/articles/PMC10043635/ /pubmed/36999097 http://dx.doi.org/10.7759/cureus.35471 Text en Copyright © 2023, Almaghrabi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Almaghrabi, Murouj Almatrafi, Shahad B Alzahrani, Asma Alharbi, Mohammed Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title | Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title_full | Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title_fullStr | Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title_full_unstemmed | Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title_short | Marked Efficacy of a Therapeutic Strategy in a Patient With Necrotizing Myopathy Associated With Anti-signal Recognition Particle (SRP) Autoantibodies |
title_sort | marked efficacy of a therapeutic strategy in a patient with necrotizing myopathy associated with anti-signal recognition particle (srp) autoantibodies |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043635/ https://www.ncbi.nlm.nih.gov/pubmed/36999097 http://dx.doi.org/10.7759/cureus.35471 |
work_keys_str_mv | AT almaghrabimurouj markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies AT almatrafishahadb markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies AT alzahraniasma markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies AT alharbimohammed markedefficacyofatherapeuticstrategyinapatientwithnecrotizingmyopathyassociatedwithantisignalrecognitionparticlesrpautoantibodies |